Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Breast Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 132 articles:
HTML format



Single Articles


    May 2020
  1. FREEDMAN RA, Sedrak MS, Bellon JR, Block CC, et al
    Weathering the Storm: Managing Older Adults with Breast Cancer Amid COVID-19 and Beyond.
    J Natl Cancer Inst. 2020 May 25. pii: 5843796. doi: 10.1093.
    PubMed     Abstract available


  2. MCCARTHY AM, Armstrong K
    Genetic Testing May Help Reduce Breast Cancer Disparities for African American Women.
    J Natl Cancer Inst. 2020 May 19. pii: 5838710. doi: 10.1093.
    PubMed    


  3. PALMER JR, Polley EC, Hu C, John EM, et al
    Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women.
    J Natl Cancer Inst. 2020 May 19. pii: 5838706. doi: 10.1093.
    PubMed     Abstract available


  4. SCHETTINI F, Giudici F, Giuliano M, Cristofanilli M, et al
    Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis.
    J Natl Cancer Inst. 2020 May 14. pii: 5837114. doi: 10.1093.
    PubMed     Abstract available


  5. KAPOOR PM, Mavaddat N, Choudhury PP, Wilcox AN, et al
    Combined associations of a polygenic risk score and classical risk factors with breast cancer risk.
    J Natl Cancer Inst. 2020 May 2. pii: 5828224. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  6. RUSHTON M, Lima I, Tuna M, Johnson C, et al
    Impact of stopping trastuzumab in early breast cancer: a population-based study in Ontario, Canada.
    J Natl Cancer Inst. 2020 Apr 28. pii: 5826355. doi: 10.1093.
    PubMed     Abstract available


  7. IZCI H, Tambuyzer T, Tuand K, Depoorter V, et al
    A Systematic Review of Estimating Breast Cancer Recurrence at the Population-Level with Administrative Data.
    J Natl Cancer Inst. 2020 Apr 7. pii: 5817318. doi: 10.1093.
    PubMed     Abstract available


  8. CANNIOTO RA, Hutson A, Dighe S, McCann W, et al
    Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival.
    J Natl Cancer Inst. 2020 Apr 2. pii: 5814214. doi: 10.1093.
    PubMed     Abstract available


    March 2020
  9. JEZEQUEL P, Patsouris A, Guette C, Juin PP, et al
    RE: Immune checkpoint profiles in luminal B breast cancer (Alliance).
    J Natl Cancer Inst. 2020 Mar 19. pii: 5810085. doi: 10.1093.
    PubMed    


  10. REINER AS, Robson ME, Mellemkjaer L, Tischkowitz M, et al
    Radiation treatment, ATM, BRCA1/2, and CHEK2*1100delC pathogenic variants, and risk of contralateral breast cancer.
    J Natl Cancer Inst. 2020 Mar 2. pii: 5771357. doi: 10.1093.
    PubMed     Abstract available


    February 2020
  11. YANG X, Song H, Leslie G, Engel C, et al
    Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D.
    J Natl Cancer Inst. 2020 Feb 28. pii: 5764125. doi: 10.1093.
    PubMed     Abstract available


  12. TERAS LR, Patel AV, Smith-Warner SA
    Re: Sustained weight loss and risk of breast cancer in women >/=50 years - Authors' Reply.
    J Natl Cancer Inst. 2020 Feb 26. pii: 5758264. doi: 10.1093.
    PubMed    


  13. FLEGAL KM
    Re: Sustained weight loss and risk of breast cancer in women >/=50 years: a pooled analysis of prospective data.
    J Natl Cancer Inst. 2020 Feb 26. pii: 5758265. doi: 10.1093.
    PubMed    


  14. HU C, Polley EC, Yadav S, Lilyquist J, et al
    The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort.
    J Natl Cancer Inst. 2020 Feb 24. pii: 5753953. doi: 10.1093.
    PubMed     Abstract available


  15. YAFFE MJ, Mainprize JG
    The Value of All-Cause Mortality as a Metric for Assessing Breast Cancer Screening.
    J Natl Cancer Inst. 2020 Feb 14. pii: 5736137. doi: 10.1093.
    PubMed     Abstract available


    January 2020
  16. ARTHUR RS, Wang T, Xue X, Kamensky V, et al
    Genetic factors, adherence to healthy lifestyle behavior, and risk of invasive breast cancer among women in the UK Biobank.
    J Natl Cancer Inst. 2020 Jan 3. pii: 5695712. doi: 10.1093.
    PubMed     Abstract available


    December 2019
  17. SEBUODEGARD S, Botteri E, Hofvind S
    Breast cancer mortality after implementation of organized population-based breast cancer screening in Norway.
    J Natl Cancer Inst. 2019 Dec 17. pii: 5678884. doi: 10.1093.
    PubMed     Abstract available


  18. TERAS LR, Patel AV, Wang M, Yaun SS, et al
    Sustained weight loss and risk of breast cancer in women >/=50 years: a pooled analysis of prospective data.
    J Natl Cancer Inst. 2019 Dec 13. pii: 5675519. doi: 10.1093.
    PubMed     Abstract available


    November 2019
  19. BRUFSKY A, Mathew A
    Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does It Matter?
    J Natl Cancer Inst. 2019 Nov 6. pii: 5613898. doi: 10.1093.
    PubMed    


    October 2019
  20. GRALOW JR, Barlow WE, Paterson AHG, Miao JL, et al
    Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307.
    J Natl Cancer Inst. 2019 Oct 31. pii: 5613900. doi: 10.1093.
    PubMed     Abstract available


  21. ANURAG M, Zhu M, Huang C, Vasaikar S, et al
    Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).
    J Natl Cancer Inst. 2019 Oct 30. pii: 5610076. doi: 10.1093.
    PubMed     Abstract available


  22. BARECHE Y, Buisseret L, Gruosso T, Girard E, et al
    Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach.
    J Natl Cancer Inst. 2019 Oct 29. pii: 5609116. doi: 10.1093.
    PubMed     Abstract available


  23. BRAUNSTEIN LZ, Riaz N
    Microenvironmental heterogeneity among triple negative breast cancer subtypes and the promise of precision medicine.
    J Natl Cancer Inst. 2019 Oct 29. pii: 5609117. doi: 10.1093.
    PubMed    


  24. HEY SP, Gyawali B, D'Andrea E, Kanagaraj M, et al
    A Systematic Review and Meta-analysis of Bevacizumab in First-line Metastatic Breast Cancer: Lessons for the Research and Regulatory Enterprises.
    J Natl Cancer Inst. 2019 Oct 25. pii: 5607300. doi: 10.1093.
    PubMed     Abstract available


  25. TORRES MA, Gogineni K, Howard DH
    Intensity-modulated radiation therapy in breast cancer patients following the release of a Choosing Wisely recommendation.
    J Natl Cancer Inst. 2019 Oct 24. pii: 5606721. doi: 10.1093.
    PubMed     Abstract available


  26. SMITH GL, Smith BD
    Sea Change: A Decade of IMRT for Treatment of Breast Cancer.
    J Natl Cancer Inst. 2019 Oct 24. pii: 5606720. doi: 10.1093.
    PubMed    


  27. RUDDY KJ, Herrin J, Sangaralingham L, Freedman RA, et al
    Follow-up care for breast cancer survivors.
    J Natl Cancer Inst. 2019 Oct 15. pii: 5587764. doi: 10.1093.
    PubMed     Abstract available


  28. FREEDMAN RA, Winer EP
    Adjuvant chemotherapy for older patients with breast cancer: When is the pain worth the gain?
    J Natl Cancer Inst. 2019 Oct 15. pii: 5573122. doi: 10.1093.
    PubMed    


  29. CHANDLER Y, Jayasekera J, Schechter C, Isaacs C, et al
    Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores.
    J Natl Cancer Inst. 2019 Oct 15. pii: 5573123. doi: 10.1093.
    PubMed     Abstract available


  30. CHECK DK, Winn AN, Fergestrom N, Reeder-Hayes KE, et al
    Concurrent Opioid and Benzodiazepine Prescriptions among Older Women Diagnosed with Breast Cancer.
    J Natl Cancer Inst. 2019 Oct 12. pii: 5586329. doi: 10.1093.
    PubMed     Abstract available


  31. SPENCER JC, Rotter JS, Eberth JM, Zahnd WE, et al
    Employment changes following breast cancer diagnosis: the effects of race and place.
    J Natl Cancer Inst. 2019 Oct 10. pii: 5585013. doi: 10.1093.
    PubMed     Abstract available


  32. DEKKERS JF, Whittle JR, Vaillant F, Chen HR, et al
    Modeling breast cancer using CRISPR/Cas9-mediated engineering of human breast organoids.
    J Natl Cancer Inst. 2019 Oct 7. pii: 5582651. doi: 10.1093.
    PubMed     Abstract available


  33. MACINNIS RJ, Liao Y, Knight JA, Milne RL, et al
    Considerations when using breast cancer risk models for women with negative BRCA1/BRCA2 mutation results.
    J Natl Cancer Inst. 2019 Oct 4. pii: 5581413. doi: 10.1093.
    PubMed     Abstract available


    September 2019
  34. MCCARTHY AM, Guan Z, Welch M, Griffin ME, et al
    Performance of breast cancer risk assessment models in a large mammography cohort.
    J Natl Cancer Inst. 2019 Sep 26. pii: 5574009. doi: 10.1093.
    PubMed     Abstract available


  35. GAIL MH
    Choosing Breast Cancer Risk Models: Importance of Independent Validation.
    J Natl Cancer Inst. 2019 Sep 26. pii: 5574008. doi: 10.1093.
    PubMed    


  36. PALMER JR
    Polygenic risk scores for breast cancer risk prediction: Lessons learned and future opportunities.
    J Natl Cancer Inst. 2019 Sep 25. pii: 5573761. doi: 10.1093.
    PubMed    


  37. SHIEH Y, Fejerman L, Lott PC, Marker K, et al
    A polygenic risk score for breast cancer in U.S. Latinas and Latin-American women.
    J Natl Cancer Inst. 2019 Sep 25. pii: 5573760. doi: 10.1093.
    PubMed     Abstract available


  38. SUNG H, Rosenberg PS, Yang XR
    Re: Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians versus the US Population.
    J Natl Cancer Inst. 2019 Sep 23. pii: 5572664. doi: 10.1093.
    PubMed    


  39. LOWRY KP, Trentham-Dietz A, Schechter CB, Alagoz O, et al
    Long-term Outcomes and Cost-effectiveness of Breast Cancer Screening with Digital Breast Tomosynthesis in the United States.
    J Natl Cancer Inst. 2019 Sep 10. pii: 5567105. doi: 10.1093.
    PubMed     Abstract available


  40. FAHRMANN JF, Vykoukal J, Fleury A, Tripathi S, et al
    Association between plasma diacetylspermine and tumor spermine synthase with outcome in triple negative breast cancer.
    J Natl Cancer Inst. 2019 Sep 10. pii: 5567103. doi: 10.1093.
    PubMed     Abstract available


  41. SHIH YT, Shen Y
    Time to Consider a Personalized Approach to Incorporate Tomosynthesis into Routine Breast Cancer Screening.
    J Natl Cancer Inst. 2019 Sep 10. pii: 5567104. doi: 10.1093.
    PubMed    


  42. DEMB J, Abraham L, Miglioretti DL, Sprague BL, et al
    Screening mammography outcomes: risk of breast cancer and mortality by comorbidity score and age.
    J Natl Cancer Inst. 2019 Sep 6. pii: 5556084. doi: 10.1093.
    PubMed     Abstract available


    August 2019
  43. COMEN EA, Bowman RL, Selenica P, Kleppe M, et al
    Evaluating clonal hematopoiesis in tumor infiltrating leukocytes in breast cancer and secondary hematologic malignancies.
    J Natl Cancer Inst. 2019 Aug 27. pii: 5555367. doi: 10.1093.
    PubMed     Abstract available


  44. SPERLING AS, Ebert BL
    CHIPing away at breast cancer.
    J Natl Cancer Inst. 2019 Aug 27. pii: 5555366. doi: 10.1093.
    PubMed    


    July 2019
  45. AZAM S, Eriksson M, Sjolander A, Hellgren R, et al
    Mammographic Density Change and Risk of Breast Cancer.
    J Natl Cancer Inst. 2019 Jul 12. pii: 5531652. doi: 10.1093.
    PubMed     Abstract available


    June 2019
  46. SACCARELLI CR, Bitencourt AGV, Morris EA
    Breast cancer screening in high-risk women: is MRI alone enough?
    J Natl Cancer Inst. 2019 Jun 24. pii: 5522375. doi: 10.1093.
    PubMed    


  47. ROSSI PG, Paci E
    RE: Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
    J Natl Cancer Inst. 2019 Jun 19. pii: 5520439. doi: 10.1093.
    PubMed    


  48. GUI Y, Liu X, Chen X, Yang X, et al
    A network meta-analysis of surgical treatment in patients with early breast cancer.
    J Natl Cancer Inst. 2019 Jun 11. pii: 5514059. doi: 10.1093.
    PubMed     Abstract available


  49. DI COSIMO S, Torri V, Porcu L
    RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
    J Natl Cancer Inst. 2019 Jun 11. pii: 5514057. doi: 10.1093.
    PubMed    


  50. CHOUDHURY PP, Wilcox AN, Brook MN, Zhang Y, et al
    Comparative validation of breast cancer risk prediction models and projections for future risk stratification.
    J Natl Cancer Inst. 2019 Jun 4. pii: 5511406. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  51. YANG Y, Wu L, Shu XO, Cai Q, et al
    Genetically predicted levels of DNA methylation biomarkers and breast cancer risk: data from 228,951 women of European descent.
    J Natl Cancer Inst. 2019 May 29. pii: 5505447. doi: 10.1093.
    PubMed     Abstract available


  52. SU Y, Huang J, Wang S, Unger JM, et al
    The Effects of Ganglioside-Monosialic Acid in Taxane-induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.
    J Natl Cancer Inst. 2019 May 15. pii: 5489913. doi: 10.1093.
    PubMed     Abstract available


  53. GOMEZ SL, Yao S, Kushi LH, Kurian AW, et al
    Is breast cancer in Asian and Asian American women a different disease?
    J Natl Cancer Inst. 2019 May 15. pii: 5489912. doi: 10.1093.
    PubMed    


  54. LIN CH, Yap YS, Lee KH, Im SA, et al
    Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians versus the US Population.
    J Natl Cancer Inst. 2019 May 15. pii: 5489914. doi: 10.1093.
    PubMed     Abstract available


  55. TESSIER L, Furzer J, Hodgson D, Cotton C, et al
    Cost-Utility of Early Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin's Lymphoma.
    J Natl Cancer Inst. 2019 May 9. pii: 5485250. doi: 10.1093.
    PubMed     Abstract available


    April 2019
  56. PRAT A, Pascual T, De Angelis C, Gutierrez C, et al
    HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.
    J Natl Cancer Inst. 2019 Apr 30. pii: 5475264. doi: 10.1093.
    PubMed     Abstract available


  57. MARIOTTO A, Jayasekerea J, Petkov V, Schechter CB, et al
    Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
    J Natl Cancer Inst. 2019 Apr 24. pii: 5475265. doi: 10.1093.
    PubMed     Abstract available


  58. MUKHOPADHYAY UK, Oturkar CC, Adams C, Wickramasekera N, et al
    TP53 Status as a Determinant of Pro- versus Anti-tumorigenic Effects of Estrogen Receptor-beta in Breast Cancer.
    J Natl Cancer Inst. 2019 Apr 16. pii: 5452444. doi: 10.1093.
    PubMed     Abstract available


  59. BADVE S, Gokmen-Polar Y
    TP53 Status and Estrogen Receptor-beta in Triple Negative Breast Cancer: Company matters.
    J Natl Cancer Inst. 2019 Apr 16. pii: 5452445. doi: 10.1093.
    PubMed    


  60. XU Z, Sandler DP, Taylor JA
    Blood DNA methylation and breast cancer: A prospective case-cohort analysis in the Sister Study.
    J Natl Cancer Inst. 2019 Apr 15. pii: 5466458. doi: 10.1093.
    PubMed     Abstract available


  61. LI N, McInerny S, Zethoven M, Cheasley D, et al
    Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.
    J Natl Cancer Inst. 2019 Apr 5. pii: 5428180. doi: 10.1093.
    PubMed     Abstract available


    March 2019
  62. KIM RS, Song N, Gavin PG, Salgado R, et al
    Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.
    J Natl Cancer Inst. 2019 Mar 19. pii: 5393262. doi: 10.1093.
    PubMed     Abstract available


  63. RODRIGUEZ-RUIZ A, Lang K, Gubern-Merida A, Broeders M, et al
    Stand-Alone Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison With 101 Radiologists.
    J Natl Cancer Inst. 2019 Mar 5. pii: 5307077. doi: 10.1093.
    PubMed     Abstract available


    February 2019
  64. KRESOVICH JK, Xu Z, O'Brien KM, Weinberg CR, et al
    Methylation-based biological age and breast cancer risk.
    J Natl Cancer Inst. 2019 Feb 22. pii: 5341521. doi: 10.1093.
    PubMed     Abstract available


  65. NGUYEN B, Veys I, Leduc S, Bareche Y, et al
    Genomic, transcriptomic, epigenetic, and immune profiling of mucinous breast cancer.
    J Natl Cancer Inst. 2019 Feb 21. pii: 5355042. doi: 10.1093.
    PubMed     Abstract available


  66. COHN BA, Cirillo PM, Terry MB
    DDT and Breast Cancer: Prospective Study of Induction Time and Susceptibility Windows.
    J Natl Cancer Inst. 2019 Feb 13. pii: 5299924. doi: 10.1093.
    PubMed     Abstract available


  67. LEE CI, Elmore JG
    Artificial Intelligence for Breast Cancer Imaging: The New Frontier?
    J Natl Cancer Inst. 2019 Feb 5. pii: 5307046. doi: 10.1093.
    PubMed    


    January 2019
  68. ABDEL-QADIR H, Thavendiranathan P, Austin PC, Lee DS, et al
    The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study.
    J Natl Cancer Inst. 2019 Jan 31. pii: 5304781. doi: 10.1093.
    PubMed     Abstract available


  69. LENIHAN DJ
    Cardiac Disease After Breast Cancer Treatment: Make Sure to Check Our Blind Spot!
    J Natl Cancer Inst. 2019 Jan 31. pii: 5304780. doi: 10.1093.
    PubMed    


  70. KRAMER I, Schaapveld M, Oldenburg HSA, Sonke GS, et al
    The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype.
    J Natl Cancer Inst. 2019 Jan 30. pii: 5304371. doi: 10.1093.
    PubMed     Abstract available


  71. CHEUNG KJ, Davidson NE
    Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era.
    J Natl Cancer Inst. 2019 Jan 28. pii: 5303805. doi: 10.1093.
    PubMed    


  72. PAREJA F, Lee JY, Brown DN, Piscuoglio S, et al
    The Genomic Landscape of Mucinous Breast Cancer.
    J Natl Cancer Inst. 2019 Jan 11. pii: 5288408. doi: 10.1093.
    PubMed     Abstract available


  73. REEVES KW, Santana MD, Manson JE, Hankinson SE, et al
    Urinary Phthalate Biomarker Concentrations and Postmenopausal Breast Cancer Risk.
    J Natl Cancer Inst. 2019 Jan 10. pii: 5284913. doi: 10.1093.
    PubMed     Abstract available


  74. HUILLARD O, Le Strat Y, Dubertret C, Goldwasser F, et al
    RE: Associations between breast cancer survivorship and adverse mental health outcomes: a systematic review.
    J Natl Cancer Inst. 2019 Jan 10. pii: 5284914. doi: 10.1093.
    PubMed    


  75. SPRAGUE BL, Kerlikowske K, Bowles EJA, Rauscher GH, et al
    Trends in Clinical Breast Density Assessment From the Breast Cancer Surveillance Consortium.
    J Natl Cancer Inst. 2019 Jan 8. pii: 5280767. doi: 10.1093.
    PubMed     Abstract available


    November 2018
  76. TERRY MB, Daly MB, Phillips KA, Ma X, et al
    Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.
    J Natl Cancer Inst. 2018 Nov 28. pii: 5212812. doi: 10.1093.
    PubMed     Abstract available


  77. HATEM E, Azzi S, El Banna N, He T, et al
    Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2018 Nov 20. pii: 5193772. doi: 10.1093.
    PubMed     Abstract available


  78. HATEM E, Azzi S, El Banna N, He T, et al
    Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2018 Nov 20. pii: 5342932. doi: 10.1093.
    PubMed     Abstract available


  79. KENSLER KH, Poole EM, Heng YJ, Collins LC, et al
    Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.
    J Natl Cancer Inst. 2018 Nov 15. pii: 5184399. doi: 10.1093.
    PubMed     Abstract available


  80. CARREIRA H, Williams R, Muller M, Harewood R, et al
    Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review.
    J Natl Cancer Inst. 2018 Nov 7. pii: 5164282. doi: 10.1093.
    PubMed     Abstract available


    October 2018
  81. QIAN F, Wang S, Mitchell J, McGuffog L, et al
    Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.
    J Natl Cancer Inst. 2018 Oct 12. pii: 5128773. doi: 10.1093.
    PubMed     Abstract available


  82. TRAPP E, Janni W, Schindlbeck C, Juckstock J, et al
    Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127124. doi: 10.1093.
    PubMed     Abstract available


  83. SPARANO JA, Henry NL
    Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127122. doi: 10.1093.
    PubMed    


  84. DESANTIS CE, Jemal A
    Re: Black-White Breast Cancer Incidence Trends: Effects of Ethnicity.
    J Natl Cancer Inst. 2018 Oct 10. pii: 5126439. doi: 10.1093.
    PubMed    


    September 2018
  85. LEE JY, Joo HS, Choi HJ, Jin S, et al
    Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.
    J Natl Cancer Inst. 2018 Sep 27. pii: 5103386. doi: 10.1093.
    PubMed     Abstract available


  86. HELZLSOUER KJ
    Can Less Be More for Individuals With Low-Risk Breast Cancer?
    J Natl Cancer Inst. 2018 Sep 18. pii: 5101448. doi: 10.1093.
    PubMed    


  87. JAYASEKERA J, Schechter CB, Sparano JA, Jagsi R, et al
    Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.
    J Natl Cancer Inst. 2018 Sep 18. pii: 5101449. doi: 10.1093.
    PubMed     Abstract available


    August 2018
  88. MARINOVICH ML, Hunter KE, Macaskill P, Houssami N, et al
    Breast Cancer Screening Using Tomosynthesis or Mammography: A Meta-analysis of Cancer Detection and Recall.
    J Natl Cancer Inst. 2018 Aug 9. pii: 5068658. doi: 10.1093.
    PubMed     Abstract available


  89. SHIMELIS H, LaDuca H, Hu C, Hart SN, et al
    Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
    J Natl Cancer Inst. 2018 Aug 7. pii: 5062996. doi: 10.1093.
    PubMed     Abstract available


    July 2018
  90. DIERAS V, Rugo HS, Schnell P, Gelmon K, et al
    Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
    J Natl Cancer Inst. 2018 Jul 18. pii: 5055701. doi: 10.1093.
    PubMed     Abstract available



  91. Corrigendum to "Cost and Complications of Local Therapies for Early-Stage Breast Cancer".
    J Natl Cancer Inst. 2018 Jul 16. pii: 5054617. doi: 10.1093.
    PubMed    


  92. LU DL, Le Cornet C, Sookthai D, Johnson TS, et al
    Circulating 27-Hydroxycholesterol and Breast Cancer Risk: Results From the EPIC-Heidelberg Cohort.
    J Natl Cancer Inst. 2018 Jul 16. pii: 5054612. doi: 10.1093.
    PubMed     Abstract available


  93. DAVIS LYNN BC, Rosenberg PS, Anderson WF, Gierach GL, et al
    Black-White Breast Cancer Incidence Trends: Effects of Ethnicity.
    J Natl Cancer Inst. 2018 Jul 5. pii: 5049141. doi: 10.1093.
    PubMed     Abstract available


    June 2018
  94. LAMBERTINI M, Campbell C, Bines J, Korde LA, et al
    Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.
    J Natl Cancer Inst. 2018 Jun 5. pii: 5033460. doi: 10.1093.
    PubMed     Abstract available


  95. CATHCART-RAKE E, Gast KC, Ruddy KJ
    What Can We Learn From Menstrual Patterns After Treatment for HER2-Positive Breast Cancer?
    J Natl Cancer Inst. 2018 Jun 5. pii: 5033462. doi: 10.1093.
    PubMed    



  96. Corrigendum to "Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer".
    J Natl Cancer Inst. 2018;110:684.
    PubMed    


    May 2018
  97. PATTERSON RE, Marinac CR, Sears DD, Kerr J, et al
    The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes.
    J Natl Cancer Inst. 2018 May 18. pii: 4999668. doi: 10.1093.
    PubMed     Abstract available


  98. LOHMANN AE, Pimentel I, Goodwin PJ
    Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer.
    J Natl Cancer Inst. 2018 May 18. pii: 4999672. doi: 10.1093.
    PubMed    


    April 2018
  99. DESMEDT C, Demicheli R, Fornili M, Bachir I, et al
    Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.
    J Natl Cancer Inst. 2018 Apr 30. pii: 4975381. doi: 10.1093.
    PubMed     Abstract available


  100. JAYASEKERA J, Li Y, Schechter CB, Jagsi R, et al
    Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.
    J Natl Cancer Inst. 2018 Apr 28. pii: 4990602. doi: 10.1093.
    PubMed     Abstract available


  101. BIDARD FC, Michiels S, Riethdorf S, Mueller V, et al
    Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
    J Natl Cancer Inst. 2018 Apr 12. pii: 4969338. doi: 10.1093.
    PubMed     Abstract available


  102. CHOI HJ, Joo HS, Won HY, Min KW, et al
    Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


  103. VERMA V, Simone CB 2nd, Mishra MV
    Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


    March 2018
  104. MATIKAS A, Foukakis T, Bergh J
    RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Mar 29. pii: 4956469. doi: 10.1093.
    PubMed    


  105. HAWK E, Maresso KC, Brown P
    NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.
    J Natl Cancer Inst. 2018 Mar 15. pii: 4938606. doi: 10.1093.
    PubMed    


  106. RITZWOLLER DP, Hassett MJ, Uno H, Cronin AM, et al
    Development, Validation, and Dissemination of a Breast Cancer Recurrence Detection and Timing Informatics Algorithm.
    J Natl Cancer Inst. 2018;110:273-281.
    PubMed     Abstract available


    February 2018
  107. GAIL MH, Pfeiffer RM
    Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening.
    J Natl Cancer Inst. 2018 Feb 27. pii: 4912416. doi: 10.1093.
    PubMed     Abstract available


  108. ZACHARIAE R, Amidi A, Damholdt MF, Clausen CDR, et al
    Internet-Delivered Cognitive-Behavioral Therapy for Insomnia in Breast Cancer Survivors: A Randomized Controlled Trial.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881759. doi: 10.1093.
    PubMed     Abstract available


  109. OESTERREICH S, Lucas PC, McAuliffe PF, Bruno TC, et al
    Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881762. doi: 10.1093.
    PubMed    


  110. DESMEDT C, Salgado R, Fornili M, Pruneri G, et al
    Immune Infiltration in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881757. doi: 10.1093.
    PubMed     Abstract available


  111. IRWIN MR
    Innovation in the Treatment of Insomnia in Breast Cancer Survivors.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881761. doi: 10.1093.
    PubMed    


  112. BROWN J, Rathbone E, Hinsley S, Gregory W, et al
    Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
    J Natl Cancer Inst. 2018 Feb 7. pii: 4842040. doi: 10.1093.
    PubMed     Abstract available


  113. BANDOS H, Melnikow J, Rivera DR, Swain SM, et al
    Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


  114. RIVERA DR, Ganz PA, Weyrich MS, Bandos H, et al
    Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


  115. JAGSI R, Momoh AO, Qi J, Hamill JB, et al
    Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


    January 2018
  116. LINDSTROM LS, Yau C, Czene K, Thompson CK, et al
    Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
    J Natl Cancer Inst. 2018 Jan 19. pii: 4780395. doi: 10.1093.
    PubMed     Abstract available


  117. OZTURK TOPCU T, Jerzak KJ, Warner E
    RE: Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2018 Jan 10. pii: 4797407. doi: 10.1093.
    PubMed    


  118. LASKY-SU JA, Zeleznik OA, Eliassen AH
    Using Metabolomics to Explore the Role of Postmenopausal Adiposity in Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795354. doi: 10.1093.
    PubMed    


  119. MOORE SC, Playdon MC, Sampson JN, Hoover RN, et al
    A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795343. doi: 10.1093.
    PubMed     Abstract available


  120. SCHRIJVER WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, et al
    Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Jan 5. pii: 4791841. doi: 10.1093.
    PubMed     Abstract available


  121. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


  122. GOLDVASER H, Barnes TA, Seruga B, Cescon DW, et al
    Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


  123. JOHNSON SB, Park HS, Gross CP, Yu JB, et al
    Use of Alternative Medicine for Cancer and Its Impact on Survival.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


    December 2017
  124. POORVU PD, Winer EP
    Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718502. doi: 10.1093.
    PubMed    


  125. KURIAN AW, Bondarenko I, Jagsi R, Friese CR, et al
    Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718501. doi: 10.1093.
    PubMed     Abstract available


  126. GLUZ O, Nitz U, Liedtke C, Christgen M, et al
    Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
    J Natl Cancer Inst. 2017 Dec 8. pii: 4698155. doi: 10.1093.
    PubMed     Abstract available


    November 2017
  127. BELKACEMI Y, Kuten A
    RE: Regional Nodal Irradiation After Breast-Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    J Natl Cancer Inst. 2017 Nov 21. pii: 4645256. doi: 10.1093.
    PubMed    


  128. MEIER M, Orr N
    Genetic Determinants of Breast Cancer Risk in Childhood Cancer Survivors.
    J Natl Cancer Inst. 2017;109.
    PubMed    


  129. MORTON LM, Sampson JN, Armstrong GT, Chen TH, et al
    Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


  130. DESHMUKH AA, Shirvani SM, Lal L, Swint JM, et al
    Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


  131. SCHWARZ LJ, Hutchinson KE, Rexer BN, Estrada MV, et al
    An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


    October 2017
  132. LAMBERTINI M, Kroman N, Ameye L, Cordoba O, et al
    Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2017 Oct 26. doi: 10.1093.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: